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In the present study, we investigated the association of the serum levels of the tumour markers carcinoembryonic antigen and
cancer antigen 15-3 with disease free survival and death from disease in 1046 women with breast cancer without metastases
at the time of primary diagnosis in relation to age and the established prognostic factors tumour size, lymph node status,
histological grading and hormone receptor status. We found that elevated pre-operative serum marker values were correlated
with early relapse (cancer antigen 15-3; P=0.0003) and death from disease (carcinoembryonic antigen, cancer antigen 15-3;
P=0.0001 both) in univariate analyses. By comparing pre- and post-operative values we found a decline in values post-surgery.
In those patients where marker levels of carcinoembryonic antigen decreased more than 33%, a signiﬁcantly higher risk for
relapse and death from disease (both P=0.0001) in univariate analyses was observed. In multivariate analysis this decrease of
carcinoembryonic antigen proved to be an independent prognostic factor. The results for cancer antigen 15-3 were
comparable to carcinoembryonic antigen in univariate analyses but showed no signiﬁcance in multivariate analysis. In this study
the post-operative decrease of the serum tumour marker carcinoembryonic antigen was a strong independent prognostic
factor for disease free survival and death from disease in breast cancer patients.
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As adjuvant therapy for breast cancer has become more generally
used, there seems to be a decreased need for prognostic factors.
Nonetheless it remains a challenge to predict which patients are
at greatest risk of relapse and thus may beneﬁt most from adjuvant
therapy (McGuire and Clark, 1992; Mansour et al, 1994). In addi-
tion to traditional prognostic factors in breast cancer such as
tumour size, axillary lymph node status, histological grading and
hormone receptor status (Clark et al, 1987; Chevallier et al, 1988;
Carter et al, 1989; Nomura et al, 1992; Carriaga and Henson,
1995), newer parameters like Her-2/neu, cathepsin D or urokinase
plasminogen activator (uPA) and plasminogen activator inhibitor 1
(PAI-1) are under consideration (Mansour et al, 1994; Schmitt et
al, 1997). Circulating tumour markers as Carcinoembryonic Anti-
gen (CEA) and Cancer Antigen 15-3 (CA 15-3) have become
well established diagnostic tools as fast, non-invasive, reproducible
and quantitative parameters in follow-up care and monitoring
therapy of breast cancer patients. However, the potential role of
these factors in prognosis has only been studied in a few investiga-
tions, which came to inconsistent conclusions (Tondini et al, 1989;
Lamerz et al, 1993; Shering et al, 1998). The only multivariate
analysis based on a large number of patients (Shering et al,
1998) investigated CA 15-3 alone.
In the present study we analysed the serum markers CEA and
CA 15-3 at the time of primary intervention, and related levels
of both markers to patient outcome using both univariate and
multivariate analysis.
MATERIALS AND METHODS
Patients
All female primary breast cancer patients, who underwent surgery
between September 1985 and June 1998 at the University Depart-
ment of Obstetrics and Gynecology, Klinikum Grosshadern,
Munich, were considered for inclusion in this retrospective study.
Patients were excluded if any other malignancy was known from
their past history or if staging investigations at the time of diagno-
sis revealed evidence of distant metastases. Furthermore, the ﬁrst
line treatment had to be surgery with curative intent, the patholo-
gical staging (tumour size and axillary lymph node status according
to the pTpN classiﬁcation) had to be known and tumour marker
values of CEA and CA 15-3 had to be available at least within
30 days preceding surgery. A total of 1046 patients fulﬁlled these
criteria. Also, histological grading, age and hormone receptor status
were evaluated at the time of diagnosis.
Patients were treated with either modiﬁed radical mastectomy or
lumpectomy and axillary node dissection with local radiotherapy
and adjuvant systemic therapy if indicated, i.e. chemotherapy in
node positive patients and hormone therapy in receptor positive
C
l
i
n
i
c
a
l
Received 4 June 2001; revised 27 November 2001; accepted 22 February
2002
*Correspondence: P Stieber; Institute of Clinical Chemistry, Klinikum der
Universita ¨tMu ¨nchen -Grosshadern-Marchioninistr. 15, D 81366 Muenchen,
Germany; E-mail: Stieber@klch.med.uni-muenchen.de
3Ahmad Fateh-Moghadam, M.D., deceased.
British Journal of Cancer (2002) 86, 1217–1222
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.compatients. Regarding the course of disease, follow-up controls were
performed with patient history, physical examination and labora-
tory tests including serum tumour markers CEA and CA 15-3,
abdominal ultrasound, chest radiography, mammography and bone
scan for detection of local or distant relapse. Additionally,
computed tomography, MRI-tomography and other radiographs
were carried out if necessary.
Patients with secondary contralateral breast cancer were
excluded with respect to disease free survival. In 844 cases data
regarding relapse were available. The median follow-up time for
patients free of relapse at the time of analysis was 2.4 (range
0.2–12.7) years, and for those with relapse 1.8 (0.2–10.4) years.
In 201 out of 844 patients recurrence of cancer occurred (ﬁrst
relapse: local recurrence n=68, distant metastases n=127, both
n=6).
Regarding death from disease, out of 1046 patients 74 were lost
to follow-up and the cause of death remained unclear in 21 cases.
Nine hundred and ﬁfty-one cases could be followed up, the
number of women years was 3434. Ten patients died of causes
other than cancer, and 95 women died from breast cancer. The
median follow-up period for patients still alive or deceased from
causes other than breast cancer was 3.0 (0.2–12.7) years and 2.9
(0.7–11.1) years for those deceased from breast cancer. The ﬁnal
data set is summarised in Table 1.
Marker analysis
The serum tumour markers CEA (IMx; MEIA, Abbott Labora-
tories, Chicago, IL, USA) and CA 15-3 (ES 700; Enzymun, Roche
Diagnostics ((previously Boehringer Mannheim) Germany) were
determined by automated test systems using sandwich ELISA assay
kits. We investigated the values of the tumour markers CEA and
CA 15-3 at the time of primary diagnosis. In addition to pre-
operative values, tumour marker concentrations could be deter-
mined in a lower number of patients after primary therapy (see
Table 1).
Statistics
Patients were grouped according to tumour size (pTis and pT1/
pT2/pT3/pT4), lymph node status, histological grading, age
(550/550 years), hormone receptor status (cut-off
15 fmol mg
71), the pre-operative tumour marker level of CEA
and CA 15-3 and the post-operative decrease of the tumour
marker. For multivariate analyses patients with tumour size pT3
and pT4 were grouped together, as well as nodal status N1 and N2.
To deﬁne cut-off values of pre-operative tumour markers, we
chose the 95%-percentile for healthy individuals of 2.0 ng ml
71
for CEA and 25 U ml
71 for CA 15-3 (Stieber, 1996). In addition
to the pre-operative value we considered the difference of
tumour-free or baseline values from initial pre-operative values.
As individual baseline value we chose the ﬁrst tumour marker
value when primary therapy, including adjuvant therapy, was
completed. For patients without adjuvant therapy the lowest value
within 6 months after primary surgery was chosen. The difference
of the pre-operative and the individual baseline value in per cent
was called the post-operative decrease (cut-off: 733%, correspond-
ing to the 90%-percentile).
Univariate survival curves for disease free survival and death
from disease were estimated by the method of Kaplan–Meier
(Kaplan and Meier, 1958) and differences between groups in survi-
val or relapse-free time were tested using the log-rank test.
Multivariate Cox regression analysis (Cox, 1972) was performed
to identify those parameters having an independent signiﬁcant
inﬂuence on DFS and DFD and to calculate the hazard ratios.
All parameters found to be signiﬁcant in univariate analyses
were entered into multivariate Cox regression model and were
excluded if their P-value was greater than 0.05. Interactions
between all variables were investigated and the assumption of
proportional hazards was tested by including time dependent vari-
ables in the model. All statistical analyses were carried out using
SAS statistic software (SAS Institute, Inc., Cary, USA).
RESULTS
Characteristics of the 1046 patients are listed in Table 1. The
median pre-operative CEA value was 1.2 ng ml
71 (range: 51–
47.8; 25%/75%-percentile: 1.0/2.3). The median pre-operative
CA 15-3 value was 17.3 U ml
71 (range 3–1686; 25%/75%-
percentile: 12.7/23.3). As shown in Figure 1, only patients with
N2 lymph node status had higher values. Post-operative tumour
marker values were available in a smaller number of patients
(CEA: n=871, CA 15-3: n=740). The median (range; 25/75%
percentile) of the baseline values after surgery was 1.0 ng ml
71
(51-15; 1.0/1.4) for CEA and 14.8 U ml
71 (3.5–120; 10.8/19.7)
for CA 15-3 (Figure 1). For the post-operative decrease the
respective values were 0% (741-100; 0/23.1) for CEA and
12.2% (743-94; 0/26.9) for CA 15-3. Tumour size, lymph node
status, histological grading as well as hormone receptor status
were found to be signiﬁcant in univariate analysis. Age had no
signiﬁcant inﬂuence on disease free survival or death from disease.
Elevated pre-operative values of CEA and CA 15-3 were associated
with early death from disease (P=0.0001 for both markers), for
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Table 1 Patient characteristics, M0, all N, N0 and N1; N2 are not listed
separately
No. of patients
all N N0 N1
T 1046 558 (53%) 457 (44%)
Tis/T1 480 (46%) 340 (61%) 134 (29%)
T2 420 (40%) 193 (34%) 218 (48%)
T3 54 (5%) 9 (2%) 44 (10%)
T4 92 (9%) 16 (3%) 61 (13%)
Grade 953 500 (52%) 425 (45%)
G1 72 (8%) 58 (12%) 14 (3%)
G2 575 (60%) 323 (65%) 241 (57%)
G3 306 (32%) 119 (24%) 170 (40%)
PR 896 463 (52%) 407 (45%)
pos 544 (61%) 301 (65%) 230 (57%)
neg 352 (39%) 162 (35%) 177 (43%)
ER 896 463 (52%) 407 (45%)
pos 598 (67%) 321 (69%) 261 (64%)
neg 298 (33%) 142 (31%) 146 (36%)
ER/PR 896 463 (52%) 407 (45%)
pos 670 (75%) 358 (77%) 294 (72%)
both neg 226 (25%) 105 (23%) 113 (28%)
Age 1046 558 (53%) 457 (44%)
550 years 327 (31%) 162 (29%) 154 (34%)
550 years 719 (69%) 396 (71%) 303 (66%)
Tumour marker
pre-op value n=1046 n=558 (53%) n=457 (44%)
CEA52n gm l
71 711 (68%) 389 (70%) 309 (68%)
CEA52n gm l
71 335 (32%) 169 (30%) 148 (32%)
CA 15-3525 U ml
71 838 (80%) 463 (83%) 356 (78%)
CA 15-3525 U ml
71 208 (20%) 95 (17%) 101 (22%)
Decrease n=871 n=443 (51%) n=402 (46%)
CEA533% 719 (83%) 391 (88%) 317 (79%)
CEA533% 152 (17%) 52 (12%) 85 (21%)
n=740 n=362 (49%) n=355 (48%)
CA 15-3533% 608 (82%) 326 (90%) 272 (77%)
CA 15-3533% 132 (18%) 36 (10%) 83 (23%)
PR=Progesterone receptor; ER=Estrogen receptor; pos=positive; neg=negative (cut-
off 15 fmol mg
71); pre-op=pre-operative; decrease=maximal decrease of the pre-
op value within 6 months post-operatively. Absolute number of patients; percentage
of parentheses.
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whereas elevated values of CEA only showed borderline signiﬁ-
cance (P=0.064). Individual baseline values as deﬁned above had
no prognostic value with either disease free survival or death from
disease, as end points.
A decrease of more than 33% of the CEA value from the pre-
operative level was associated with early relapse and death from
disease (both P=0.0001). A decrease of CA 15-3 of more than
33% was an indication of bad prognosis (death from disease
P=0.007; disease free survival P=0.0087).
Kaplan–Meier curves for DFS and DFD are shown for the
combination of pre-operative value and post-operative decrease
of CEA and CA 15-3, respectively (Figures 2 and 3). Those patients
whose elevated pre-operative values of CA 15-3 decreased more
than 33% had the highest risk of relapse and death from cancer
(Figure 2). In contrast to CA 15-3, the CEA decrease alone, inde-
pendent from the level of the pre-operative value, was a strong
predictor for early relapse and death of breast cancer (Figure 3).
In multivariate analysis, independent prognostic factors for DFS
in 658 patients with 160 recurrences were tumour size, lymph node
status, hormone receptors and decrease of the pre-operative CEA
value 433% (Table 2). It is notable that 1 year after primary ther-
apy the hazard ratio for relapse for both decrease of CEA values
and progesterone receptor diminished compared with the initial
risk. Tumour grade, CA 15-3 and pre-operative values of CEA were
without signiﬁcance for relapse.
In 720 patients with 74 tumour associated deaths, tumour
size, lymph node status, hormone receptor status and the
decrease of CEA were independent predictors for death from
disease in multivariate analysis (Table 2). In contrast to
relapse-free survival, only the hazard ratio for the hormone
receptor status was inﬂuenced by time, the decrease of CEA
level showed no time dependency. Likewise as for DFS, grading,
CA 15-3 and the pre-operative values of CEA were without
inﬂuence on death from disease.
DISCUSSION
CEA and CA 15-3 are the most thoroughly investigated serum
tumour markers in breast cancer. It is generally agreed that tumour
markers in breast cancer patients are not a tool for primary diagno-
sis, because of their low sensitivity and speciﬁcity (Tondini et al,
1989; Fateh-Moghadam and Stieber, 1993; Lamerz et al, 1993). Their
use for early detection of metastases seems to be promising (Lamerz
et al, 1991; Stieber et al, 1992; Vizcarra et al, 1994; O’Hanlon et al,
1995) and their use for measuring therapeutic response in metastatic
disease is widely accepted (Tondini et al, 1988; Dnistrian et al, 1991;
Robertson et al, 1991; Saﬁ et al, 1991). Many studies tried to assess
the prognostic role of these tumour markers (some analysed in
serum, some in tissue), but most of them had low patient numbers
or short follow-up periods, and used only univariate analyses (Myers
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Figure 1 Values of CEA and CA 15-3 pre-operatively and post-
operative baseline values.
Table 2 Independent prognostic factors for disease free survival and death from disease; multivariate analysis
Variable Exposition Hazard ratio after PT CI 95% P value Hazard ratio after 1 year
Disease free survival
Tumour size T2 vs Tis/1 1.8 1.4–2.2 50.001 1.8
T3/4 vs T2
Lymph node N1/2 vs N0 1.6 1.1–2.3 0.007 1.6
PR neg. vs pos. 3.5 2.0–6.0 50.001 2.8
PR6time 0.026
Decrease CEA 5 vs 5 33% 2.7 1.5–4.8 0.001 2.0
Decr. CEA6time 0.044
Death from disease
Tumour size T2 vs Tis/1 2.1 1.5–3.0 50.001 2.1
T3/4 vs T2
Lymph node N1/2 vs N0 2.7 1.5–4.8 50.001 2.7
PR neg. vs pos. 5.8 2.2–15.2 50.001 4.5
PR6time 0.036
Decrease CEA 5 vs 5 33% 2.7 1.7–4.4 0.001 2.7
CI: Conﬁdence interval; PT: primary treatment; decrease (decr.)=maximal decrease of the pre-operative value within 6 months post-
operatively; neg.=negative; pos.=positive.
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Mansour et al, 1983; Kallioniemi et al, 1988; Hammer et al, 1992;
O’Hanlon et al, 1995). To our knowledge, there is no multivariate
analysis on CEA in serum, only a few studies performed multivariate
analyses on CEA in breast cancer tissue (Esteban et al, 1994; Sund-
blad et al, 1996). Among the two multivariate analyses of CA 15-3 in
serum at the time of diagnosis of breast cancer (Gion et al, 1991;
Shering et al, 1998), only Shering had a sufﬁciently high number
of patients. To date, no study has tested both tumour markers
CEA and CA 15-3 for independent prognostic value at the time of
primary intervention in breast cancer patients.
In the present study, we investigated the association of the
serum levels of the tumour markers CEA and CA 15-3 with DFS
and DFD in women with breast cancer without metastases at the
time of primary diagnosis, in relation to age and the established
prognostic factors tumour size, lymph node status, histological
grading and hormone receptor status. In accordance to other
studies, we found tumour size, lymph nodes, histological grading
and hormone receptors to be prognostically signiﬁcant for DFS
and DFD (Chevallier et al, 1988; Carter et al, 1989; Nomura et
al, 1992; Carriaga and Henson, 1995).
In most patients, tumour marker levels were found to be very
low (Figures 1 and 2), but were higher than average levels in
healthy women (CEA 1.0 ng ml
71; CA 15-3 13.6 U ml
71) (Stieber,
1996). We deﬁned the marker cut-off values in our study by the 95
%-percentile of healthy individuals (2.0 ng ml
71 for CEA and
25 U ml
71 for CA 15-3).
We found that elevated pre-operative serum marker values were
correlated with early relapse (CA 15-3; P=0.0003) and death from
disease (CEA, CA 15-3; P=0.0001 both) in univariate analyses.
Possibly, the release of tumour associated antigens at the time of
diagnosis proves blood supply respectively vascularisation of the
tumour and by consequence the possibility of already existing
micrometastases and bad prognosis from the beginning (Gasparini
et al, 1997).
By comparing pre- and post-operative values we found a decline in
values post-surgery. The post-operative marker values we determined
were well comparable to the median of healthy individuals which
could be expected as we investigated only patients with complete
resection of the tumour (R0 resection). Therefore it is understandable
thatwe found no signiﬁcant correlation with the recurrence of disease
assessing isolated post-operative marker values of CEA and CA 15-3.
Other studies that found an association between elevated post-opera-
tive levels of CEA and recurrence of disease had only small patient
numbers, short follow up and partly investigated advanced stages
of disease (Myers et al, 1978; Hammer et al, 1992). This is one of
the ﬁrst studies to relate changes in serum marker levels following
surgery to patient outcome.
In those patients where marker levels of CEA decreased more
than 33%, a signiﬁcantly higher risk for relapse and death from
disease (both P=0.0001) in univariate analyses was observed. The
general opinion that R0-resection corresponds to good prognosis
is not in contradiction to our ﬁndings, because we only observed
patients with complete resection of the tumour.
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Figure 3 Disease free survival (A, log-rank test: P=0.0003) and survival
until death of disease (B, log-rank test: P=0.0001) according to CEA pre-
operative values and post-operative decrease.
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the decrease only for CEA, whereas for CA 15-3 a signiﬁcant worse
prognosis can be seen only for patients with high pre-operative
tumour marker values and signiﬁcant decrease after surgery
(Figures 2 and 3). This could probably be due to the fact that
up to now the reproducibility of CA 15-3 values at low concentra-
tions is unsatisfactory.
In multivariate analysis, this decrease of CEA proved to be an
independent prognostic factor (Table 2). The results for CA 15-3
were comparable to CEA in univariate analyses but showed no
signiﬁcance in multivariate analysis at least when both markers
were included in the model simultaneously. This could be due to
the fact that the correlation with tumour size is higher for CA
15-3 than for CEA.
As we determined both markers, CEA and CA 15-3, it is difﬁcult
to compare our study with the two other relevant studies of Gion
and Shering (Gion et al, 1991; Shering et al, 1998). Although Gion
found, in accordance to us, that pre-operative serum levels of CA
15-3 had no prognostic relevance in multivariate analysis, the
number of patients and the unknown number of relapse and death
from disease is probably too small to give reliable results.
In contrast Shering et al (1998) reported on a high number of
patients and found a prognostic relevance for pre-operative CA
15-3 values. The prognostic relevance of a single factor in multi-
variate analysis depends on which and how other factors are
included in the model. Thus, our results would be similar to
those of Shering et al (1998), if CEA was not included in the
analysis.
Conclusion
In this study the post-operative decrease of the serum tumour
marker CEA was a strong independent prognostic factor for disease
free survival and death from disease in breast cancer patients. To
our knowledge, this is the ﬁrst study reporting on the high prog-
nostic relevance of the decline of tumour associated antigens. It
is also the largest study to-date to have analysed the prognostic
value of serum tumour markers in breast cancer. An advantage
of our approach for clinical practice would be the independence
from tumour tissue.
In addition to those prognostic factors being already indica-
tive for adjuvant therapy like lymph nodes and grading, a
randomized prospective therapy intervention study based on
the decrease of CEA would be needed to prove the relevance
of our ﬁndings.
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